Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 9/2005

01.09.2005 | Original Paper

Overexpression of CC3/TIP30 is associated with HER-2/neu status in breast cancer

verfasst von: Dao-Hai Zhang, Lee Lee Wong, Lee Kian Tai, Evelyn SC Koay, Robert E Hewitt

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose: The human CC3/TIP30 gene is a putative metastasis suppressor gene, based on the results of experimental studies using lung, colon and melanoma cell lines. However, there is very little evidence from studies on clinical material, in support of such a role for the gene. In this study, we evaluated the expression of CC3/TIP30 in human breast cancer tissue and investigated the possible associations with the clinicopathological parameters. Methods: Total RNA and proteins were extracted from the frozen breast tumor and matched normal tissues. Evaluation of CC3/TIP30 expression was assessed by reverse transcription (RT)-PCR and reverse phase protein array. Immunohistochemistry of CC3/TIP30 on breast tissue microarrays was also analyzed. Results: We have found that CC3/TIP30 expression is significantly associated with positive HER-2/neu status at both mRNA (P=0.023) and protein (P=0.016) levels. Immunohistochemical analysis on tissue microarrays also shows a positive correlation between CC3 expression and HER-2/neu status (P=0.0028). Conclusion: Our findings suggest a potential link between the expression of CC3/TIP30 gene and the HER-2/neu oncogene-mediated signal pathway.These findings could not have been predicted from previous experimental studies, and suggest that CC3/TIP30 may play a complex role in breast cancer.
Literatur
Zurück zum Zitat Baker ME, Yan L, Pear MR (2000) Three-dimensional model of human TIP30, a coactivator for HIV-1 Tat-activated transcription, and CC3, a protein associated with metastasis suppression. Cell Mol Life Sci 57:851–858CrossRefPubMed Baker ME, Yan L, Pear MR (2000) Three-dimensional model of human TIP30, a coactivator for HIV-1 Tat-activated transcription, and CC3, a protein associated with metastasis suppression. Cell Mol Life Sci 57:851–858CrossRefPubMed
Zurück zum Zitat Hays DF, Thor AD (2002) c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29:231–245CrossRefPubMed Hays DF, Thor AD (2002) c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29:231–245CrossRefPubMed
Zurück zum Zitat Hewitt RE, Brown KE, Corcoran ML, Stetler-Stevenson WG (2000) Increased expression of tissue inhibitor of metalloproteinases type I (TIMP-I) in a more tumorigenic colon cancer cell line. J Path 192:455–459CrossRefPubMed Hewitt RE, Brown KE, Corcoran ML, Stetler-Stevenson WG (2000) Increased expression of tissue inhibitor of metalloproteinases type I (TIMP-I) in a more tumorigenic colon cancer cell line. J Path 192:455–459CrossRefPubMed
Zurück zum Zitat Ito M, Jiang C, Krumm K, Zhang X, Pecha J, Zhao J, Guo Y, Roeder RG, Xiao H (2003) TIP30 deficiency increases susceptibility to tumorigenesis. Cancer Res 63:8763–8767PubMed Ito M, Jiang C, Krumm K, Zhang X, Pecha J, Zhao J, Guo Y, Roeder RG, Xiao H (2003) TIP30 deficiency increases susceptibility to tumorigenesis. Cancer Res 63:8763–8767PubMed
Zurück zum Zitat Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H (2004) TIP30 interacts with an estrogen receptor α-interacting coactivator CIA and regulated c-myc transcription. J Biol Chem 279:27781–27789CrossRefPubMed Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H (2004) TIP30 interacts with an estrogen receptor α-interacting coactivator CIA and regulated c-myc transcription. J Biol Chem 279:27781–27789CrossRefPubMed
Zurück zum Zitat King FW, Shtivelman E (2004) Inhibition of nuclear import by the proapoptotic protein CC3. Mol Cell Biol 24:7091–7101CrossRefPubMed King FW, Shtivelman E (2004) Inhibition of nuclear import by the proapoptotic protein CC3. Mol Cell Biol 24:7091–7101CrossRefPubMed
Zurück zum Zitat Liu Y, Thor A, Shtivelman E, Cao Y, Tu G, Heath TD, Debs RJ (1999) Systemic gene delivery expands the repertoire of effective antiangiogenic agents sensitizing cell to apoptosis. J Biol Chem 274:13338–13344CrossRefPubMed Liu Y, Thor A, Shtivelman E, Cao Y, Tu G, Heath TD, Debs RJ (1999) Systemic gene delivery expands the repertoire of effective antiangiogenic agents sensitizing cell to apoptosis. J Biol Chem 274:13338–13344CrossRefPubMed
Zurück zum Zitat NicAmhlaoibh R, Shtivelman E (2001) Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. Oncogene 20:270–275CrossRefPubMed NicAmhlaoibh R, Shtivelman E (2001) Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. Oncogene 20:270–275CrossRefPubMed
Zurück zum Zitat Shtivelman E (1997) A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 14:2167–2173CrossRefPubMed Shtivelman E (1997) A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 14:2167–2173CrossRefPubMed
Zurück zum Zitat Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Odar S (2002) Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 79:216–223CrossRefPubMed Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Odar S (2002) Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 79:216–223CrossRefPubMed
Zurück zum Zitat Whitman S, Wang X, Shalaby R, Shtivelman E (2000) Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Mol Cell Biol 20:583–593CrossRefPubMed Whitman S, Wang X, Shalaby R, Shtivelman E (2000) Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Mol Cell Biol 20:583–593CrossRefPubMed
Zurück zum Zitat Xiao H, Tao Y, Greenblatt J, Roeder RG (1998) A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription. Proc Natl Acad Sci USA 95:2146–2151CrossRefPubMed Xiao H, Tao Y, Greenblatt J, Roeder RG (1998) A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription. Proc Natl Acad Sci USA 95:2146–2151CrossRefPubMed
Zurück zum Zitat Xiao H, Palhan V, Yang Y, Roeder RG (2000) TIP30 has an intrinsic kinase activity required for up-regulation of a subset of apoptotic genes. EMBO J 19:956–963CrossRefPubMed Xiao H, Palhan V, Yang Y, Roeder RG (2000) TIP30 has an intrinsic kinase activity required for up-regulation of a subset of apoptotic genes. EMBO J 19:956–963CrossRefPubMed
Zurück zum Zitat Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(suppl 2):1–13CrossRefPubMed Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(suppl 2):1–13CrossRefPubMed
Zurück zum Zitat Zhang D-H, Salto-Tellez M, Do E, Putti TC, Koay ESC (2003a) Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34:362–368CrossRefPubMed Zhang D-H, Salto-Tellez M, Do E, Putti TC, Koay ESC (2003a) Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34:362–368CrossRefPubMed
Zurück zum Zitat Zhang D-H, Salto-Tellez M, Putti TC, Do E, Koay ESC (2003b) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Path 16:79–85CrossRefPubMed Zhang D-H, Salto-Tellez M, Putti TC, Do E, Koay ESC (2003b) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Path 16:79–85CrossRefPubMed
Metadaten
Titel
Overexpression of CC3/TIP30 is associated with HER-2/neu status in breast cancer
verfasst von
Dao-Hai Zhang
Lee Lee Wong
Lee Kian Tai
Evelyn SC Koay
Robert E Hewitt
Publikationsdatum
01.09.2005
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2005
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-005-0674-z

Weitere Artikel der Ausgabe 9/2005

Journal of Cancer Research and Clinical Oncology 9/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.